JPRN-UMIN000006838已完成未知
Multicenter pahse II tiral of combination therapy using abraxane and trastuzumab +-pertuzumab for HER2-positive locally advanced or metastatic breast cancer - Combination therapy of abraxane and trastuzumab+- pertuzumab
Department of Breast and Endocrine Surgery, Hyogo College of Medicine0 个研究点目标入组 21 人开始时间: 2011年12月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 21
研究概览
简要总结
Retrospective-prospective study was conducted with eribulin or nab-paclitzxel + trastuzumab + pertuzumab. Progression-free survival was significantly improved in patients with baseline absolute lymphocyte count more than 1500 (p=0.0106).
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) With history of hypersensitivity reaction for paclitaxel, trastuzumab, and pertuzumab. 2) With serious drug allergy 3) Pregnant or nursing women 4) With active another cancer 5) With widespread liver metastases or pulmonary lymphangitis with dyspnea 6) With brain metastasis with symptom 7) With uncontrollable hypertension, angina pectoris, congestive heart failure, myocardial infection within 1 year, arrhythmia that need treat, valvular heart disease 8) Poorly controlled diabetes 9) With pulmonary fibrosis or pneumonitis 10) With dyspnea at rest (due to metastatic lung lesion and cardiovascular disease) 11) With pleural effusion, ascites, and pericardial effusion that need treat 12) Infection or possible infection associated with clinical symptoms such as fever 13) Patients have active hepatitis type B 14) Cases who physician judged improper to entry this trial
研究者
相似试验
已完成
不适用
Combination therapy of Eribulin, Trastuzumab and Pertuzumab for the treatment of patients with previously treated advanced HER2-positive breast cancer.Breast cancerJPRN-UMIN000012018Mie University Hospital10
已完成
3 期
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + TrastuzumabBreast CancerNCT03264547Japan Breast Cancer Research Group446
招募中
1 期
Pembrolizumab, Ibrutinib and Rituximab in PCNSLRecurrent CancerRefractory CancerRelapsed CancerPrimary Central Nervous System LymphomaNCT04421560Dana-Farber Cancer Institute37
已完成
2 期
Prospective study of Eribulin plus Trastuzumab in patients with HER-2 positive metastatic breast cancer (KSCOG-BC06)HER2 positive metastatic breast cancerJPRN-UMIN000010761Kurume University School of Medicine Department of Surgery30
已完成
2 期
A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue SarcomasUndifferentiated Pleomorphic SarcomaSarcomaLiposarcomaLeiomyosarcomaNCT03899805Dana-Farber Cancer Institute57